Compositions of a polyorthoester and an organic acid excipient

Inventors

Ottoboni, Thomas B. • Girotti, Lee Ann Lynn

Assignees

Heron Therapeutics LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10980886-B2

Patent

Publication Date

2021-04-20

Expiration Date


Abstract

Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an organic acid excipient, and a basic drug are described, along with related methods.

Core Innovation

The invention relates to biodegradable polyorthoester-based semi-solid delivery compositions that include a polyorthoester, maleic acid, and an aprotic solvent selected from N-methyl-2-pyrrolidone (NMP) and dimethyl sulfoxide (DMSO), with a therapeutically active agent dispersed or solubilized in the composition. The therapeutically active agent is an amino-amide anesthetic selected from bupivacaine, levobupivacaine, dibucaine, mepivacaine, procaine, lidocaine, tetracaine, and ropivacaine.

Maleic acid is present in less than an equimolar amount when compared to the therapeutically active agent, such that the therapeutic agent is present as a mixed salt-base. The composition is substantially free of crystals of the therapeutically active agent, thereby inhibiting or impeding crystallization of the anesthetic.

By using the maleic acid in a sub-equimolar amount together with the specified polyorthoester/semi-solid composition components, the delivery composition enhances the drug release rate. The described outcomes include in vitro release of at least about 75–80 wt% over about 1–5 days, typically less than or equal to 4 days, compared with a composition lacking organic acid where release over more than 5 days is indicated.

Claims Coverage

The independent claim covers a biodegradable polyorthoester semi-solid delivery composition with 4 principal inventive elements: the polyorthoester matrix, maleic acid present at less than an equimolar amount, an aprotic solvent selected from NMP or DMSO, and an amino-amide anesthetic dispersed or solubilized such that the anesthetic forms a mixed salt-base and the composition is substantially free of anesthetic crystals. The dependent claims further refine the scope by narrowing the anesthetic selection, specifying free base form and whether the anesthetic is solubilized, and constraining the polyorthoester structures to Formulas I–IV with detailed substituent and parameter ranges, with Formula III highlighted.

Polyorthoester with maleic acid in sub-equimolar amount

A composition comprising a polyorthoester and maleic acid, wherein maleic acid is present in less than an equimolar amount when compared to the therapeutically active agent, such that the therapeutic agent is present as a mixed salt-base and the composition is substantially free of crystals of the therapeutically active agent.

Aprotic solvent selected from NMP or DMSO

A composition comprising an aprotic solvent selected from N-methyl-2-pyrrolidone (NMP) and dimethyl sulfoxide (DMSO).

Amino-amide anesthetic dispersed or solubilized

A composition wherein the therapeutically active agent is an amino-amide anesthetic selected from the group consisting of bupivacaine, levobupivacaine, dibucaine, mepivacaine, procaine, lidocaine, tetracaine, and ropivacaine, and wherein the therapeutically active agent is dispersed or solubilized in the composition.

Polyorthoester structural formulas with parameter constraints

The polyorthoester is selected from polyorthoesters represented by Formulas I, II, III, or IV, wherein substituent variables and polymerization parameters meet the stated structural and integer/range constraints, including constraints on R*, A, n and other defined variables.

Overall, the claim coverage centers on combining a polyorthoester semi-solid composition with maleic acid at less than an equimolar amount relative to an amino-amide anesthetic, using an aprotic solvent selected from NMP or DMSO, to yield a mixed salt-base form that is substantially free of anesthetic crystals. Dependent claims narrow anesthetic selection and form and restrict the polyorthoester to Formulas I–IV, with additional emphasis on Formula III structural and parameter constraints.

Stated Advantages

The composition is substantially free of crystals of the therapeutically active agent.

Maleic acid is described as stabilizing basic amino-amide local anesthetics against crystallization and accelerating drug release early in delivery.

Enhancing drug release rate, with described in vitro release of at least about 75–80 wt% over about 1–5 days, typically less than or equal to 4 days.

Inhibiting or impeding crystallization of the therapeutically active agent.

Documented Applications

Local anesthesia delivery using amino-amide anesthetics, including bupivacaine or ropivacaine, from biodegradable polyorthoester-based semi-solid delivery compositions.

Local anesthesia/peripheral nerve block context, including a canine study and drug release/crystallization assessments in vitro.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.